A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

Recruiting now

Conditions studied: Arthritis, Polymyalgia Rheumatica, Immune Checkpoint Inhibitors

In brief

To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.

Key facts

Study ID

NCT06647134

Run by

M.D. Anderson Cancer Center

People needed

20

Starts

2024-09-11

Expected to finish

2028-03-31

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The criteria are:
• Patients aged 18 years and above
• English (conversational level) speaking, with the ability to give informed consent
• Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy

You may not qualify if…

• Acutely life-threatening or worsening cancer
• Hearing impairment functionally limiting participation in verbal interview

Where it is running

• MD Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.